Main Menu

ESMO 2022: Cancer researchers rendezvous in Paris


ICR scientists will be presenting at this years ESMO annual meeting. We take a look at some of the presentations.

Posted on 07 September, 2022 by Julia Bakker

ESMO 2022 logo

We take a look at some exciting research being presented by scientists from The Institute of Cancer Research and our collaborators at this years’ ESMO annual meeting.

Next week clinical oncologists and cancer researchers from around the world will unite in Paris to present, debate and discuss the latest advances in cancer research.

Taking place between 9-13 September, the European Society for Medical Oncology (ESMO) Congress – one of Europe’s biggest annual cancer conferences – is back on-site. It will surely have a celebratory feel, including networking opportunities and the excitement of meeting colleagues face to face – although the full programme will be available digitally for delegates who cannot attend in person.

As ever, ICR scientists will be there to present some of our latest scientific discoveries and results from cutting-edge clinical trials.

We’ll be highlighting some presentations involving science from researchers at the ICR and our partner hospital The Royal Marsden NHS Foundation Trust prior to, and during ESMO 2022.

Access the full programme

Presentations to look out for

  • Abstract 454O on findings from a phase I/II trial of AZD5069 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer, presented by Dr Christina Guo
  • Poster 827P on a phase I trial of a modified virus, RP2, as a single agent and combined with nivolumab in patients with solid tumours, presented by Professor Kevin Harrington 
  • Abstract 1358O on transcriptome signatures during treatment for advanced prostate cancer, an ancillary study of the STAMPEDE trial led by Professor Nick James, presented by Dr Marina Parry, UCL Cancer Institute
  • Abstract LBA62 on a phase III trial comparing the efficacy of abiraterone in combination with enzalutamide, compared to abiraterone alone in patients with advanced, hormone sensitive prostate cancer. The study was led by Professor Nick James and Professor Chris Parker and results will be presented by Professor Gert Attard, UCL Cancer Institute
  • Abstract 1359MO on a study comparing treatment response depending on nodal characteristics of metastases as part of the STAMPEDE trial which is led by Professor Nick James. The research is being presented by A Harran, Royal United Hospitals Bath
  • Abstract 529MO on findings of the phase II MEDIOLA trial comparing olaparib with durvalumab with or without bevacizumab in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer, presented by Dr Susana Banerjee
  • Poster 1697P on treatment-induced cancer evolution in BRCA-mutant and non BRCA-mutant ovarian cancer models, led by Professor Udai Banerji, presented by Dr Alvaro H. Ingles Russo Garces at The Royal Marsden
  • Poster 1368P on a study exploring whether tumour genetics are linked to prolonged benefits of talazoparib in metastatic castration-resistant prostate cancer with DNA damage response alterations, presented by Professor Johann de Bono
  • Abstract LBA9 on first results from the RADICALS-HD trial looking at the duration of radiotherapy and hormone therapy after surgery for prostate cancer, presented by Professor Chris Parker
  • Abstract 457MO on a phase I study M1774 in patients with solid tumours led by Professor Johann de Bono and presented by Dr Timothy Yap, The University of Texas M. D. Anderson Cancer Center, Houston, US

Keep up to speed with ESMO 2022

There are many more presentations from research involving ICR researchers, and other collaborative trials involving ICR researchers being presented. Keep an eye out on our website and follow us on Twitter to keep up to speed!


comments powered by Disqus